The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $412.79

Today's change0.00 0.00%
Updated March 3 4:15 PM EST. Delayed by at least 15 minutes.
 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $412.79

Today's change0.00 0.00%
Updated March 3 4:15 PM EST. Delayed by at least 15 minutes.

Biogen Idec Inc closed at (U.S.)$412.79.

Over the last five days, shares have gained 1.95% and 21.61% year to date. Shares have outperformed the S&P 500 by 7.79% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $412.79
  • High--
  • Low--
  • Bid / Ask(U.S.) $400.72 / (U.S.) $415.63
  • YTD % change+21.61%
  • Volume0
  • Average volume (10-day)1,061,543
  • Average volume (1-month)1,375,591
  • Average volume (3-month)1,723,199
  • 52-week range(U.S.) $272.02 to (U.S.) $416.82
  • Beta1.05
  • Trailing P/E33.34×
  • P/E 1 year forward24.34×
  • Forward PEG1.40×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $12.38
Updated March 3 4:15 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+30.47%

Based on its net profit margin of 30.47%, Biogen Idec Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue2,6412,5112,4212,130
Total other revenue--------
Total revenue2,6412,5112,4212,130
Gross profit2,3432,2092,1301,851
Total cost of revenue297303292279
Total operating expense1,4811,3591,4331,458
Selling / general / administrative574570577512
Research & development500417447529
Depreciation / amortization107122117143
Interest expense (income), net operating--------
Unusual expense (income)3-540-5
Other operating expenses, total0000
Operating income1,1601,153989671
Interest income (expense), net non-operating-7-7-7-8
Gain (loss) on sale of assets--------
Other--------
Income before tax1,1511,136994666
Income after tax883862725487
Income tax, total268275269178
Net income883857715480
Total adjustments to net income--------
Net income before extra. items883857715480
Minority interest11-90
Equity in affiliates0-5-2-8
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items883857715480
Inc. avail. to common incl. extra. items883857715480
Diluted net income883857715480
Dilution adjustment0------
Diluted weighted average shares236237237238
Diluted EPS excluding extraordinary itemsvalue per share3.743.623.012.02
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share3.753.443.012.00